CYBN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q3

FY2026Q4

FY2027Q1

-0.591

+59.26%

-0.569

-46.83%

-0.585

-26.82%

Estimates Revision

Stock Price

Go Up

+32.27%

In Past 3 Month

6 Analyst Rating

Wall Street analysts forecast CYBN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CYBN is 45.00 USD with a low forecast of 30.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

30.00

Averages

45.00

High

55.00

Current: 0.000

Low

30.00

Averages

45.00

High

55.00

Guggenheim

Buy

maintain

$39 -> $48

2025-12-03

Reason

Guggenheim

Price Target

$39 -> $48

2025-12-03

maintain

Buy

Reason

Guggenheim raised the firm's price target on Cybin to $48 from $39 and keeps a Buy rating on the shares. Noting that the company's Phase 3 program for CYB003 in adjunctive MDD is advancing as planned, the firm says it expects Cybin to have "a strong 2026 performance."

Canaccord

Buy

downgrade

$70 -> $45

2025-11-20

Reason

Canaccord

Price Target

$70 -> $45

2025-11-20

downgrade

Buy

Reason

Canaccord lowered the firm's price target on Cybin to $45 from $70 and keeps a Buy rating on the shares. The firm updated its model to reflect its recent capital raise of about $175M and paydown of its convertible debt. The company is poised for a catalyst rich 2026 and shares remain significantly undervalued.

H.C. Wainwright

Buy

downgrade

$150 -> $55

2025-11-14

Reason

H.C. Wainwright

Price Target

$150 -> $55

2025-11-14

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Cybin to $55 from $150 and keeps a Buy rating on the shares. Strong clinical execution, commercial groundwork, and financial strengthening leave Cybin well-positioned ahead of two major 2026 readouts, the firm says. The increased share count from the recent financing, normalization of expenses in Wainwright's model, and fine-tuning its expected CYB003 launch to 2028 and CYB004 launch to 2029 resulted in a revised price target, Wainwright adds.

Canaccord

Buy

downgrade

$73 -> $70

2025-07-08

Reason

Canaccord

Price Target

$73 -> $70

2025-07-08

downgrade

Buy

Reason

Canaccord lowered the firm's price target on Cybin to $70 from $73 and keeps a Buy rating on the shares. The firm noted they recently reported its F4Q25 results and operating expenses came in close to estimates. The key update were that the company is on track to complete its Phase 2 study for CYB004 (deuterated DMT) for generalized anxiety disorder (GAD) in mid- C2025E; and report Phase 3 data for CYB003 (deuterated psilocin analog) for major depressive disorder (MDD) in C2026E. Canaccord continues to believe Cybin is significantly undervalued ahead of data.

Lucid Capital

NULL

Buy

initiated

$106

2025-06-06

Reason

Lucid Capital

Price Target

$106

2025-06-06

initiated

NULL

Buy

Reason

Lucid Capital initiated coverage of Cybin with a Buy rating and $106 price target. Cybin is developing alternative formulations and derivatives of psychedelic drugs, the analyst tells investors in a research note. The firm points out the Drug Enforcement Agency classifies both of Cybin's drugs as Schedule I, meaning "drugs with no currently accepted medical use and high potential for abuse."

Guggenheim

Eddie Hickman

Strong Buy

Initiates

$35

2025-03-13

Reason

Guggenheim

Eddie Hickman

Price Target

$35

2025-03-13

Initiates

Strong Buy

Reason

Guggenheim initiated coverage of Cybin with a Buy rating and $35 price target.

Valuation Metrics

The current forward P/E ratio for Cybin Inc (CYBN.A) is -3.49, compared to its 5-year average forward P/E of -3.90. For a more detailed relative valuation and DCF analysis to assess Cybin Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.90

Current PE

-3.49

Overvalued PE

-1.78

Undervalued PE

-6.03

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-8.78

Current EV/EBITDA

-2.46

Overvalued EV/EBITDA

1.62

Undervalued EV/EBITDA

-19.18

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

43.62

Current PS

0.00

Overvalued PS

266.56

Undervalued PS

-179.33

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CYBN News & Events

Events Timeline

No data

News

7.5

01-04Yahoo Finance

Organigram Expands Investment in Phylos to $10 Million for Cannabis Genetics

8.5

2025-12-31Benzinga

Cybin Inc Launches $100 Million Equity Program, Shares Drop 6.6%

5.0

2025-12-31Benzinga

Vanda Pharmaceuticals' NEREUS Receives FDA Approval, Shares Surge 17.5%

People Also Watch

Frequently Asked Questions

What is Cybin Inc (CYBN) stock price today?

The current price of CYBN is 8.4 USD — it has increased 1.21 % in the last trading day.

What is Cybin Inc (CYBN)'s business?

Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N, N-dimethyltryptamine (DMT) and dDMT programs create a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II.CYB005 is in Preclinical stage. It has an intellectual property portfolio in the psychedelic drug development sector with over 80 patents granted and over 230 patent applications pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.

What is the price predicton of CYBN Stock?

What is Cybin Inc (CYBN)'s revenue for the last quarter?

Cybin Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Cybin Inc (CYBN)'s earnings per share (EPS) for the last quarter?

Cybin Inc. EPS for the last quarter amounts to -1.39 USD, decreased -33.81 % YoY.

What changes have occurred in the market's expectations for Cybin Inc (CYBN)'s fundamentals?

The market is revising No Change the revenue expectations for CYBN for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 32.27%.

How many employees does Cybin Inc (CYBN). have?

Cybin Inc (CYBN) has 50 emplpoyees as of January 08 2026.

What is Cybin Inc (CYBN) market cap?

Today CYBN has the market capitalization of 200.95M USD.